Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions
Jessica Chu(Bristol-Myers Squibb (United States)), Hong Shen, Anthony M. Marino(Bristol-Myers Squibb (United States)), Omprakash Patil(Bristol-Myers Squibb (India)), Linna Wang(Bristol-Myers Squibb (Germany)), Michael Sinz(Rutgers, The State University of New Jersey), Salil D. Desai(Bristol-Myers Squibb (India)), Erika Panfen(Bristol-Myers Squibb (United States)), Xueqing Chen(Brigham and Women's Hospital), R. Marcus Fancher(Bristol-Myers Squibb (United States)), Raviraj Landage(Bristol-Myers Squibb (India)), Yongjun Xue(Bristol-Myers Squibb (Germany)), Devang Shah(Bristol-Myers Squibb (United States))
Cited by 7
Related Papers
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312
Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole
|Oncogene|2006|211
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
|Antimicrobial Agents and Chemotherapy|2012|186
Pharmacokinetic Drug Interactions Involving 17??-Ethinylestradiol
|Clinical Pharmacokinetics|2007|174